Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 455

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study

Open access
Valle, Juan W., Palmer, Daniel, Jackson, Richard, Cox, Trevor, Neoptolemos, John P., Ghaneh, Paula, Rawcliffe, Charlotte L., Bassi, Claudio, Stocken, Deborah D., Cunningham, David, O'Reilly, Derek, Goldstein, David, Robinson, Bridget A., Karapetis, Christos, Scarfe, Andrew, Lacaine, Francois, Sand, Juhani, Izbicki, Jakob R., Mayerle, Julia, Dervenis, Christos, Oláh, Attila, Butturini, Giovanni, Lind, Pehr A., Middleton, Mark R., Anthoney, Alan, Sumpter, Kate, Carter, Ross, Büchler, Markus W.·2014·Journal of Clinical Oncology

Abstract

Purpose: Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate chemotherapy is unknown. Patients and Methods: Patients with pancreatic ductal adenocarcinoma treated within the international, phase III, European Study Group for Pancreatic Cancer–3 (version 2) study were included if they had been randomly assigned to chemotherapy. Overall survival analysis was performed on an intention-to-treat basis, retaining patients in their randomized groups, and adjusting the overall treatment effect by known prognostic variables as well as the start time of chemotherapy. Results: There were 985 patients, of whom 486 (49%) received gemcitabine and 499 (51%) received fluorouracil; 675 patients (68%) completed all six cycles of chemotherapy (full course) and 293 patients (30%) completed one to five cycles. Lymph node involvement, resection margins status, tumor differentiation, and completion of therapy were all shown by multivariable Cox regression to be independent survival factors. Overall survival favored patients who completed the full six courses of treatment versus those who did not (hazard ratio [HR], 0.516; 95% CI, 0.443 to 0.601; P < .001). Time to starting chemotherapy did not influence overall survival rates for the full study population (HR, 0.985; 95% CI, 0.956 to 1.015). Chemotherapy start time was an important survival factor only for the subgroup of patients who did not complete therapy, in favor of later treatment (P < .001). Conclusion: Completion of all six cycles of planned adjuvant chemotherapy rather than early initiation was an independent prognostic factor after resection for pancreatic adenocarcinoma. There seems to be no difference in outcome if chemotherapy is delayed up to 12 weeks, thus allowing adequate time for postoperative recovery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.50.7657

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 455

Metadata

Authors
Valle, J. W., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., Rawcliffe, C. L., Bassi, C., Stocken, D. D., Cunningham, D., O'Reilly, D., Goldstein, D., Robinson, B. A., Karapetis, C., Scarfe, A., Lacaine, F., Sand, J., Izbicki, J. R., Mayerle, J., Dervenis, C., Oláh, A., Butturini, G., Lind, P. A., Middleton, M. R., Anthoney, A., Sumpter, K., Carter, R., & Büchler, M. W.
Venue
Journal of Clinical Oncology
Published
2014-02-20
Volume
32
Issue
6
Pages
504-512
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2129884672
Cited by
455
References
39
FWCI
18.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. https://app.cochat.ai/papers/10.1200/jco.2013.50.7657
The paper
Valle, J. W., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., Rawcliffe, C. L., Bassi, C., Stocken, D. D., Cunningham, D., O'Reilly, D., Goldstein, D., Robinson, B. A., Karapetis, C., Scarfe, A., Lacaine, F., Sand, J., Izbicki, J. R., Mayerle, J., . . . Büchler, M. W. (2014). Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.50.7657

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.